Cefiderocol
Edina Avdic, Pharm.D.
Pediatric Dosing Author:
Bethany Sharpless Chalk, Pharm.D., BCPPS
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
FDA
Patients ≥18 y/o for the treatment of the following infections caused by susceptible Gram-negative microorganisms:
Complicated urinary tract infections (cUTI)
, including
pyelonephritis
Hospital-acquired bacterial pneumonia and
ventilator-associated bacterial pneumonia
(HABP/VABP)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
NON-FDA APPROVED USES
MDR GNR (e.g.
Pseudomonas
,
Acinetobacter
, CRO) infections when no other alternatives are available
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2025 Unbound Medicine, Inc. All rights reserved